Literature DB >> 24500540

Skeletal response to resistance and impact training in prostate cancer survivors.

Kerri M Winters-Stone1, Jessica C Dobek, Jill A Bennett, Gianni F Maddalozzo, Christopher W Ryan, Tomasz M Beer.   

Abstract

INTRODUCTION: Androgen deprivation therapy (ADT) is associated with significant bone loss and an increase in fracture risk among prostate cancer survivors (PCS). We investigated whether impact + resistance training could stop ADT-related declines in bone mineral density (BMD) among PCS on ADT.
METHODS: We randomized 51 PCS (mean age, 70.2 yr) currently prescribed ADT to participate in 1 yr of impact + resistance training (Prevent Osteoporosis with Impact + Resistance (POWIR)) or in an exercise placebo program of stretching exercise (FLEX). Outcomes were proximal femur (total hip, femoral neck, and greater trochanter) and spine (L1-L4) BMD (g·cm) and bone turnover markers (serum osteocalcin (ng·mL) and urinary deoxypyrodinoline cross-links (nmol·mmol Cr)).
RESULTS: Retention in the 1-yr study was 84% and median attendance to supervised classes was 84% in POWIR and 74% in FLEX. No study-related injuries were reported. There were no significant differences between groups for average L1-L4 BMD or for BMD at any hip site. When examining individual vertebrae, POWIR has a significant effect on preservation of BMD (-0.4%) at the L4 vertebrae compared with losses (-3.1%) in FLEX (P = 0.03).
CONCLUSION: Impact + resistance training was a safe and acceptable form of exercise for older PCS on ADT. Among our limited sample, POWIR did not appear to have a clinically meaningful effect on hip or spine BMD, but some evidence of skeletal adaptation to resistance + impact training in an androgen-deprived state was apparent. Future studies need to be conducted on a larger sample of patients and should consider modifications to POWIR that could further enhance loading across the spine and at the hip to preserve BMD at these clinically relevant sites.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24500540      PMCID: PMC4101037          DOI: 10.1249/MSS.0000000000000265

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  37 in total

1.  Effect of low-repetition jump training on bone mineral density in young women.

Authors:  Takeru Kato; Toru Terashima; Takenori Yamashita; Yasuhiko Hatanaka; Akiko Honda; Yoshihisa Umemura
Journal:  J Appl Physiol (1985)       Date:  2005-11-03

2.  Summary of the International Society For Clinical Densitometry 2005 Position Development Conference.

Authors:  Neil Binkley; John P Bilezikian; David L Kendler; Edward S Leib; E Michael Lewiecki; Steven M Petak
Journal:  J Bone Miner Res       Date:  2007-05       Impact factor: 6.741

3.  Site-specific response of bone to exercise in premenopausal women.

Authors:  Kerri M Winters-Stone; Christine M Snow
Journal:  Bone       Date:  2006-07-28       Impact factor: 4.398

4.  Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

Authors:  Christopher W Ryan; Dezheng Huo; Laurence M Demers; Tomasz M Beer; Leo V Lacerna
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

5.  Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.

Authors:  Matthew R Smith; Won Chan Lee; Jane Brandman; Qin Wang; Marc Botteman; Chris L Pashos
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

6.  Resistance training and reduction of treatment side effects in prostate cancer patients.

Authors:  Daniel A Galvão; Kazunori Nosaka; Dennis R Taaffe; Nigel Spry; Linda J Kristjanson; Michael R McGuigan; Katsuhiko Suzuki; Kanemitsu Yamaya; Robert U Newton
Journal:  Med Sci Sports Exerc       Date:  2006-12       Impact factor: 5.411

Review 7.  Bone health in men receiving androgen deprivation therapy for prostate cancer.

Authors:  James A Eastham
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

8.  Pre- and postmenopausal women have different bone mineral density responses to the same high-impact exercise.

Authors:  E J Bassey; M C Rothwell; J J Littlewood; D W Pye
Journal:  J Bone Miner Res       Date:  1998-12       Impact factor: 6.741

9.  Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.

Authors: 
Journal:  Menopause       Date:  2010 Jan-Feb       Impact factor: 2.953

Review 10.  Prostate specific antigen recurrence after definitive therapy.

Authors:  Stephen J Freedland; Judd W Moul
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

View more
  38 in total

1.  Football training in men with prostate cancer undergoing androgen deprivation therapy: activity profile and short-term skeletal and postural balance adaptations.

Authors:  Jacob Uth; Therese Hornstrup; Jesper F Christensen; Karl B Christensen; Niklas R Jørgensen; Eva W Helge; Jakob F Schmidt; Klaus Brasso; Jørn W Helge; Markus D Jakobsen; Lars L Andersen; Mikael Rørth; Julie Midtgaard; Peter Krustrup
Journal:  Eur J Appl Physiol       Date:  2015-11-30       Impact factor: 3.078

Review 2.  The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review.

Authors:  T Hasenoehrl; M Keilani; T Sedghi Komanadj; M Mickel; M Margreiter; M Marhold; R Crevenna
Journal:  Support Care Cancer       Date:  2015-05-24       Impact factor: 3.603

3.  Benefits of partnered strength training for prostate cancer survivors and spouses: results from a randomized controlled trial of the Exercising Together project.

Authors:  Kerri M Winters-Stone; Karen S Lyons; Jessica Dobek; Nathan F Dieckmann; Jill A Bennett; Lillian Nail; Tomasz M Beer
Journal:  J Cancer Surviv       Date:  2015-12-29       Impact factor: 4.442

4.  Evidence on physical activity and osteoporosis prevention for people aged 65+ years: a systematic review to inform the WHO guidelines on physical activity and sedentary behaviour.

Authors:  Marina B Pinheiro; Juliana Oliveira; Adrian Bauman; Nicola Fairhall; Wing Kwok; Catherine Sherrington
Journal:  Int J Behav Nutr Phys Act       Date:  2020-11-26       Impact factor: 6.457

5.  Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.

Authors:  J Uth; T Hornstrup; J F Christensen; K B Christensen; N R Jørgensen; J F Schmidt; K Brasso; M D Jakobsen; E Sundstrup; L L Andersen; M Rørth; J Midtgaard; P Krustrup; E W Helge
Journal:  Osteoporos Int       Date:  2015-11-16       Impact factor: 4.507

Review 6.  Weight loss and bone mineral density.

Authors:  Gary R Hunter; Eric P Plaisance; Gordon Fisher
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

Review 7.  The use of exercise interventions to overcome adverse effects of androgen deprivation therapy.

Authors:  Peter Busch Østergren; Caroline Kistorp; Finn Noe Bennedbæk; Jens Faber; Jens Sønksen; Mikkel Fode
Journal:  Nat Rev Urol       Date:  2016-04-26       Impact factor: 14.432

8.  Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial.

Authors:  Kerri M Winters-Stone; Jessica C Dobek; Jill A Bennett; Nathan F Dieckmann; Gianni F Maddalozzo; Christopher W Ryan; Tomasz M Beer
Journal:  Arch Phys Med Rehabil       Date:  2014-09-03       Impact factor: 3.966

9.  The effect of exercise on bone mineral density in adult cancer survivors: a systematic review and meta-analysis.

Authors:  J Dalla Via; R M Daly; S F Fraser
Journal:  Osteoporos Int       Date:  2017-10-02       Impact factor: 4.507

Review 10.  Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.

Authors:  Arif Hussain; Abhishek Tripathi; Christopher Pieczonka; Diane Cope; Andrea McNatty; Christopher Logothetis; Theresa Guise
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-10-07       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.